We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00672165
Recruitment Status : Completed
First Posted : May 6, 2008
Last Update Posted : February 26, 2015
National Cancer Institute (NCI)
Actinium Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2015
  Study Completion Date : February 2015